Nixon Peabody Trust’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Nixon Peabody Trust’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56	Closed	-$1.13K	–	182
2026 Q1	$1.13K	Hold	56	–	–	﹤0.01%	160
2025 Q4	$37.3K	Hold	56	–	–	﹤0.01%	160
2025 Q3	$18.1K	Hold	56	–	–	﹤0.01%	152
2025 Q2	$18.4K	Hold	56	–	–	﹤0.01%	148
2025 Q1	$14.8K	Hold	56	–	–	﹤0.01%	152
2024 Q4	$20.8K	Hold	56	–	–	﹤0.01%	146
2024 Q3	$8.64K	Hold	56	–	–	﹤0.01%	139
2024 Q2	$8.35K	Hold	56	–	–	﹤0.01%	128
2024 Q1	$11.8K	Hold	56	–	–	﹤0.01%	126
2023 Q4	$11.7K	Buy	+56	New	+$11.2K	﹤0.01%	130

Other funds holding IRLA

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nixon Peabody Trust's IRLA Position: Q2 2026 in Review

Nixon Peabody Trust sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 56 shares — an estimated $1.13K sold.

Nixon Peabody Trust first reported a position in IRLA in Q4 2023 and held it in 10 quarters. The position peaked at $37.3K in Q4 2025. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

Nixon Peabody Trust reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
Nixon Peabody Trust sold 56 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $1.13K.
Nixon Peabody Trust first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2023 and held it in 10 quarters.
Nixon Peabody Trust's IRulya Therapeutics Inc. Common Stock position peaked at $37.3K in Q4 2025.
26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Nixon Peabody Trust's 13F filing for Q2 2026, filed 27 Jul 2026.